Literature DB >> 27217852

Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study.

Libni J Eapen1, Edward Jones2, Wassim Kassouf3, Carole Lambert4, Scott C Morgan1, Madeleine Moussa5, Robert Nam6, Matthew Parliament7, Laurie Russell7, Fred Saad8, D Robert Siemens5, Luis Souhami3, Ewa Szumacher6, Scott Tyldesley2, Yan Xu1, Ingrid Zbieranowski6, Rodney H Breau1, Eric Belanger1, Peter Black2, Eric Estey7, Julie Bowan9, Bishwajit Bora9, Michael Brundage10, Peter Chung11, Neil Fleshner11, Andrew Evans11, Glenn Bauman12, Jonathan Izawa12, Chris Davidson5, Fadi Brimo3.   

Abstract

INTRODUCTION: We aimed to enumerate the rate of pelvic recurrence following radical cystectomy at university-affiliated hospitals in Canada.
METHODS: Canadian, university-affiliated hospitals were invited to participate. They were asked to identify the first 10 consecutive patients undergoing radical cystectomy starting January 1, 2005, who had urothelial carcinoma stages pT3/T4 N0-2 M0. The first 10 consecutive cases starting January 1, 2005 who met these criteria were the patients submitted by that institution with information regarding tumour stage, age, number of nodes removed, and last known clinical status in regard to recurrence and patterns of failure.
RESULTS: Of the 111 patients, 80% had pT3 and 20% pT4 disease, with 62% being node-negative, 14% pN1, and 27% pN2; 57% had 10 or more nodes removed. Cumulative incidence of pelvic relapse was 40% among the entire group.
CONCLUSIONS: This review demonstrates a high rate of pelvic tumour recurrence following radical cystectomy for pT3/T4 urothelial cancer.

Entities:  

Year:  2016        PMID: 27217852      PMCID: PMC4840007          DOI: 10.5489/cuaj.3456

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  13 in total

1.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

Authors:  J P Stein; G Lieskovsky; R Cote; S Groshen; A C Feng; S Boyd; E Skinner; B Bochner; D Thangathurai; M Mikhail; D Raghavan; D G Skinner
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

2.  External validation of a model to predict locoregional failure after radical cystectomy.

Authors:  Michael Froehner; Vladimir Novotny; Manfred P Wirth; Sabine Brookman-May; Atiqullah Aziz; Matthias May
Journal:  Cancer       Date:  2014-07-12       Impact factor: 6.860

3.  Risk prediction models of locoregional failure after radical cystectomy for urothelial carcinoma: external validation in a cohort of korean patients.

Authors:  Ja Hyeon Ku; Myong Kim; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038

4.  Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710.

Authors:  John P Christodouleas; Brian C Baumann; Jiwei He; Wei-Ting Hwang; Kai N Tucker; Justin E Bekelman; Catherine M Tangen; Seth P Lerner; Thomas J Guzzo; S Bruce Malkowicz; Harry Herr
Journal:  Cancer       Date:  2014-01-03       Impact factor: 6.860

Review 5.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

Authors:  Arnulf Stenzl; Nigel C Cowan; Maria De Santis; Markus A Kuczyk; Axel S Merseburger; Maria José Ribal; Amir Sherif; J Alfred Witjes
Journal:  Eur Urol       Date:  2011-03-23       Impact factor: 20.096

6.  Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study.

Authors:  Pascal Zehnder; Urs E Studer; Eila C Skinner; Ryan P Dorin; Jie Cai; Beat Roth; Gus Miranda; Frédéric Birkhäuser; John Stein; Fiona C Burkhard; Sia Daneshmand; George N Thalmann; Inderbir S Gill; Donald G Skinner
Journal:  J Urol       Date:  2011-08-17       Impact factor: 7.450

7.  Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer.

Authors:  Harry W Herr; Bernard H Bochner; Guido Dalbagni; S Machele Donat; Victor E Reuter; Dean F Bajorin
Journal:  J Urol       Date:  2002-03       Impact factor: 7.450

8.  Surveillance strategies after definitive therapy of invasive bladder cancer.

Authors:  Ilias Cagiannos; Christopher Morash
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

9.  Surgical factors influence bladder cancer outcomes: a cooperative group report.

Authors:  Harry W Herr; James R Faulkner; H Barton Grossman; Ronald B Natale; Ralph deVere White; Michael F Sarosdy; E David Crawford
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

10.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

View more
  3 in total

1.  Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.

Authors:  Mohamed S Zaghloul; John P Christodouleas; Andrew Smith; Ahmed Abdallah; Hany William; Hussein M Khaled; Wei-Ting Hwang; Brian C Baumann
Journal:  JAMA Surg       Date:  2018-01-17       Impact factor: 14.766

Review 2.  The Rationale for Post-Operative Radiation in Localized Bladder Cancer.

Authors:  Brian C Baumann; Paul Sargos; Libni J Eapen; Jason A Efstathiou; Ananya Choudhury; Amit Bahl; Vedang Murthy; Leslie K Ballas; Valérie Fonteyne; Pierre M Richaud; Mohamed S Zaghloul; John P Christodouleas
Journal:  Bladder Cancer       Date:  2017-01-27

3.  Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?

Authors:  Kevin Lm Chua; Grace Kusumawidjaja; Jure Murgic; Melvin Lk Chua
Journal:  ESMO Open       Date:  2017-03-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.